You may have seen headlines recently claiming peptides like MOTS C or BPC 157 are back let's talk about what this means. In 2023, the FDA placed 19 commonly used peptides into Category FDA Moves to Exclude Semaglutide, Tizerpatide, and Liraglutide from 503B Bulk Substances List Lengea Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification FDA to review broader access to restricted peptides in July